Menu
Not yet recruiting NCT05983094

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Phase II Interventional Breast Cancer Neoadjuvant Therapy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Utidelone, Carboplatin, Epirubicin, Trastuzumab.
Who it may be relevant to
Registry conditions: Breast Cancer, Neoadjuvant Therapy. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.

Detailed description

This is a single arm, multi-center study,three-cohort, prospective phase II study which will enroll 181 high-risk early-stage or locally advanced breast cancer patients.

Interventions

  • Drug Utidelone
    Utidelone injection 30mg/m2, on days 1-5 of each cycle
  • Drug Carboplatin
    Carboplatin Area under curve(AUC)6, iv, was administered on day 1
  • Drug Epirubicin
    Epirubicin 75mg/m2 was administered on day 1
  • Drug Trastuzumab
    Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
  • Drug Pertuzumab
    Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles

Primary outcome measures

  • Total pathological complete response (etpCR, Pathologic staging after neoadjuvant therapy(yp)T0/is, (yp)N0) [Time frame: 24 months]
Secondary outcome measures (5)
  • Breast Pathologic Complete Response ((bpCR, Pathologic staging after neoadjuvant therapy(yp)T0/is) [Time frame: 24 months]
  • Event Free Survival(EFS) of 2 years [Time frame: 24 months]
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Time frame: Through study completion，an average of 1 year]
  • Patient reported outcome (PRO) [Time frame: Through study completion，an average of 1 year]
  • Patient reported outcome (PRO) [Time frame: Through study completion，an average of 1 year]

Eligibility criteria

Inclusion criteria

  • Female patients who will receive initial treatment, 18-70 years of age；
  • Newly diagnosed high-risk early stage (T1c-2, N1; T2, N0) and locally advanced (T1c-2, N2-3; T3-4, N0-3) breast cancer (tumor stage II, III), in which HR+/HER2- T2, N0 patients need to be accompanied by high-risk factors (histological grade 3 or Ki67 ≥ 20%). Triple negative breast cancer(TNBC), HER2 positive (Immunohistochemical(IHC)3+; IHC 2+, FISH amplification) breast cancer, HR negative HER2 IHC 2+ and undetermined result of FISH, HR positive HER2 negative (IHC 0,1+; 2+, FISH amplification) breast cancer confirmed by pathological test.
  • Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1
  • The blood routine examination was basically normal (CTCAE ≤ 1) within one week before enrollment (based on the normal values of each research center laboratory). No Human Granulocyte Colony Stimulating Factor(rhGCSF) or blood transfusion/erythropoietin(EPO) or other drugs were used within 14 days prior to enrollment.

White blood cell count (WBC) ≥ 4 x109 / L; Neutrophil count (ANC) > 1.5x109 / L; Platelet count (PLT) ≥ 100×109/L Hemoglobin(Hb) ≥ 100g/L.

  • The blood biochemistry examination was basically normal (CTCAE ≤ 1) within one week before enrollment (based on the normal values of each research center laboratory) Serum total bilirubin ≤ Upper limit of normal value(ULN)； Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 1.5×ULN； Alkaline phosphatase ≤ 2.5×ULN； Serum creatinine ≤ 1.5×ULN.
  • Color Doppler echocardiography left ventricular Ejection fraction (LVEF) ≥ 55%
  • Female patients with fertility must agree to use effective contraceptive methods during the study period and within 6 months of the last study medication. The Pregnancy test (urine or serum) must be negative
  • Be willing and able to provide written informed consent/assent for the trial.

Exclusion criteria

  • Primary stage IV breast cancer；
  • Inflammatory breast cancer;
  • Bilateral primary breast cancer (including invasive cancer and carcinoma in situ)；
  • Previous anti-cancer treatment or radiotherapy for any malignant tumor, excluding cured cervical Carcinoma in situ, skin Basal-cell carcinoma and squamous cell carcinoma.
  • Receive any sex hormone treatment (such as contraceptives, ovarian hormone replacement therapy, etc.), except for Ovarian function suppression（OFS）fertility protection, or any hormone drugs (such as Raloxifene, tamoxifen, or other selective estrogen receptor modulators) to treat osteoporosis or prevent breast cancer；
  • The patient has undergone major surgery unrelated to breast cancer within 4 weeks before treatment or has not yet fully recovered;
  • Symptomatic peripheral neuropathy CTCAE 5.0 grade ≥ 2
  • Serious cardio cerebral Vascular disease, including but not limited to the followings:
  • History of congestive heart failure or systolic dysfunction (LVEF<50%);
  • Angina pectoris requiring anti angina drugs;
  • High risk uncontrolled arrhythmias or severe conduction abnormalities, such as ventricular arrhythmias that require clinical intervention, II-III degree atrioventricular block, etc; Under resting state, the average corrected Q-T interval(QTcF) of three 12 lead electrocardiogram examinations is>470ms;
  • Clinically significant heart valve disease with cardiac dysfunction;
  • Hypertension that cannot be controlled;
  • History of myocardial infarction
  • Allergic to any component of any drug in this protocol.
  • Those who are not suitable for using Corticosteroid.
  • Individuals with active infections who currently require systematic anti infection treatment.
  • History of immune deficiency disease, including positive of HIV/AIDS, or other acquired or congenital immune deficiency diseases, or having a history of organ transplantation.
  • Who had participated in other drug intervention clinical trials within the 28 days of randomization, or who is participating in another clinical trial or is using other investigational treatments.
  • Individuals in pregnancy (positive Pregnancy test) and lactation.
  • Any other comorbidities that interfere with the implementation of the treatment plan, or the researcher evaluate that the subject has a history of other serious systemic diseases, or other reasons lead to the patients is unsuitable to participate in this trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Cancer Hospital, Chinese Academy of Medical Sciences — Beijing

Identifiers

NCT: NCT05983094 · NCC4047

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗